Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Neuroscience Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
J Med Virol. 2021 Mar;93(3):1314-1319. doi: 10.1002/jmv.26593. Epub 2020 Oct 30.
Recent evidence suggested that neurological manifestations occur in patients with a severe form of coronavirus disease (COVID-19). On the basis of this issue, neurologists are very concerned about patients with neurological disorders, especially multiple sclerosis (MS), as consumers of immunosuppressive or immune-modulating drugs. Therefore, the administration of proper disease-modifying therapies (DMTs) in MS patients is critical during the pandemic status. On the one hand, both the autoimmune diseases and immunosuppressive drugs increase the risk of infection due to impairment in the immune system, and on the other hand, postponing of MS treatment has serious consequences on the central nervous system. In the present study, we discussed recent literature about the effect of DMTs administration on the severity of COVID-19 in the MS patients. Overall, it seems that DMTs do not provoke the COVID-19 infection in the MS patients by declining immune responses and cytokine storm. However, as a precaution, the supervision of a neurologist is highly recommended.
最近的证据表明，严重形式的冠状病毒病（COVID-19）患者会出现神经表现。基于这个问题，神经科医生非常关注患有神经系统疾病的患者，特别是多发性硬化症（MS）患者，因为他们是免疫抑制剂或免疫调节剂药物的使用者。因此，在大流行期间，MS 患者的适当疾病修正治疗（DMT）非常关键。一方面，由于免疫系统受损，自身免疫性疾病和免疫抑制剂都会增加感染的风险，另一方面，推迟 MS 治疗会对中枢神经系统产生严重后果。在本研究中，我们讨论了最近关于 DMT 给药对 MS 患者 COVID-19 严重程度影响的文献。总的来说，似乎 DMT 通过降低免疫反应和细胞因子风暴并没有引发 MS 患者的 COVID-19 感染。然而，作为预防措施，强烈建议由神经科医生进行监督。
